uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Clinical relevance of dissolution testing in quality by design
Show others and affiliations
2008 (English)In: AAPS Journal, ISSN 1550-7416, Vol. 10, no 2, 380-390 p.Article, review/survey (Refereed) Published
Abstract [en]

Quality by design (QbD) has recently been introduced in pharmaceutical product development in a regulatory context and the process of implementing such concepts in the drug approval process is presently on-going. This has the potential to allow for a more flexible regulatory approach based on understanding and optimisation of how design of a product and its manufacturing process may affect product quality. Thus, adding restrictions to manufacturing beyond what can be motivated by clinical quality brings no benefits but only additional costs. This leads to a challenge for biopharmaceutical scientists to link clinical product performance to critical manufacturing attributes. In vitro dissolution testing is clearly a key tool for this purpose and the present bioequivalence guidelines and biopharmaceutical classification system (BCS) provides a platform for regulatory applications of in vitro dissolution as a marker for consistency in clinical outcomes. However, the application of these concepts might need to be further developed in the context of QbD to take advantage of the higher level of understanding that is implied and displayed in regulatory documentation utilising QbD concepts. Aspects that should be considered include identification of rate limiting steps in the absorption process that can be linked to pharmacokinetic variables and used for prediction of bioavailability variables, in vivo relevance of in vitro dissolution test conditions and performance/interpretation of specific bioavailability studies on critical formulation/process variables. This article will give some examples and suggestions how clinical relevance of dissolution testing can be achieved in the context of QbD derived from a specific case study for a BCS II compound.

Place, publisher, year, edition, pages
2008. Vol. 10, no 2, 380-390 p.
National Category
Pharmaceutical Sciences
URN: urn:nbn:se:uu:diva-100027DOI: 10.1208/s12248-008-9034-7ISI: 000259133600019PubMedID: 18686045OAI: oai:DiVA.org:uu-100027DiVA: diva2:209201
Available from: 2009-03-24 Created: 2009-03-24 Last updated: 2010-11-25Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Pharmacy
In the same journal
AAPS Journal
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 210 hits
ReferencesLink to record
Permanent link

Direct link